

Synthetic studies of the HIV-1 protease inhibitive didemnaketals: precise and stereocontrolled synthesis of the key mother spiroketal

Xue Zhi Zhao, Lei Peng, Meng Tang, Yong Qiang Tu* and Shuan Hu Gao


Department of Chemistry and State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, PR China

Received 2 May 2005; revised 2 June 2005; accepted 29 July 2005

Abstract—The precise and stereocontrolled synthesis of the C₉–C₂₃ portion, the key mother spiroketal of the HIV-1 protease inhibitive didemnaketals from the ascidian *Didemnum* sp., has been carried out through multisteps starting from (*R*)-pulegone as the chiral template. This approach involved the distereoselective construction of eight chiral centers by intramolecular chiral inducement and the coupling of two fragments by Julia reaction.
© 2005 Published by Elsevier Ltd.

Didemnaketals **A** (**1**) and **B** (**2**) (Scheme 1) were isolated by Faulkner and co-workers from the ascidian *Didemnum*

in 1991 and exhibited to be highly inhibitive to HIV-1 protease with the IC₅₀ being 2 and 10 μM, respectively.¹



Scheme 1. Didemnaketal **A**, **B**, **C** and retrosynthesis of the C₉–C₂₃ spiroketal portion.


Keywords: Key mother spiroketal; HIV-1 protease; Intramolecular chiral inducement; Julia reaction.

* Corresponding author. Tel.: +86 931 8912410; fax: +86 931 8912582; e-mail: tuyq@lzu.edu.cn

Previously, we had designed and synthesized their spiroketals portion vaguely.² However in 2002, Faulkner and co-workers modified and finished the full relative and absolute stereochemistry of the didemnaketals,³ which makes us design another asymmetric total synthesis of this kind of compounds. Recently, we performed the precise synthesis of the ester side-chain (the C₁–C₈ portion).⁴ Here, we present our stereocontrolled synthesis of the C₉ to C₂₃ spiroketal portion **4** of the didemnaketals, which have eight precise stereocenters (10*S*,11*S*,12*S*,14*S*,16*S*,18*R*,20*S*,21*S*).


Our synthesis, shown in the retrosynthetic analysis (Scheme 1), was based on the selection of (*R*)-pulegone **8** as a starting material, as its (*R*)-Me could generate a series of conjoint stereocenters in compound **6** (C₁₀–C₁₂) and **7** (C₂₀–C₂₁). Aldehyde **6** and sulfone **7** could be coupled by Julia reaction and then ketone **5** would be prepared, which could be spiroketalized to the key mother spiroketal **4**.

Firstly, we prepare the acetal **9** in two isomers (1/1) from (*R*)-pulegone **8** with 13% yield through seven steps.² The transacetalization of **9** with 1,3-thiopropanol produced α -hydroxyl ketone **10**. The α -hydroxyl ketone **10** was reduced to triol **11** with 82% de value and 85% yield by DIBAL-H.⁵ Selective protection of two secondary hydroxyl groups in **11** with TBSCl to afford alcohol **12**, which upon dehydration of the tertiary hydroxyl group, gave the compound **13** with the terminal double bond. Subsequently, diastereoselective hydroboration of the double bond in compound **13** with 9-BBN⁶ followed by oxidative workup afforded the hydroxyl compound



Scheme 2. Reagents and conditions: (a) CH₂(CH₂SH)₂, BF₃·Et₂O, CH₂Cl₂, 0 °C, 53%; (b) DIBAL-H, THF, –78 °C, 85%; (c) TBSCl, imid., DMF, 90 °C, 78%; (d) SOCl₂, Py, 0 °C, 76%; (e) (i) 9-BBN, THF, –78 °C; (ii) H₂O₂, NaOH, 0 °C, 82% (two steps); (f) TBDPSCl, imid., DMF, rt, 95%; (g) NBS, acetone, rt, 67%.

14 in which the three conjoint stereocenters were constructed successfully. The subsequent protection of the



Scheme 3. Reagents and conditions: (a) NaBH₄, CeCl₃·7H₂O, MeOH, 0 °C, 87%; (b) TBDPSCl, imid., DMF, rt, 95%; (c) K₂OsO₄·H₂O, NMO, ^tBuOH–acetone–H₂O (1:2:1), 86%; (d) Ac₂O, DMAP, Py, rt, 97%; (e) SOCl₂, Py, 0 °C, 98%; (f) O₃, CH₂Cl₂, –78 °C, 78%; (g) KBH(OAc)₃, PhH, rt, 82%; (h) CH₂(CH₂SH)₂, BF₃·Et₂O, CH₂Cl₂, 0 °C, 78%; (i) I₂, imid., PPh₃, PhCH₃, 0 °C, 81%; (j) PhSO₂Na, DMF, rt, 93%; (k) KOH, H₂O, MeOH, reflux; (l) DMP, TsOH, rt, 90% (two steps).





Figure 1. Crystal structure of compound **25**.



Scheme 4. Reagents and conditions: (a) n -BuLi, THF, -78°C , then **6**, THF, -78°C , 75%; (b) (i) CrO_3 , Py, CH_2Cl_2 , 0°C , 74%; (ii) Na–Hg, MeOH, NaH_2PO_4 , rt, 63%; (c) HF (40%), CH_3CN , rt, 35%.

hydroxyl group and deacetalization generated the aldehyde **6** as a C_9 – C_{16} fragment of didemnaketals (Scheme 2).

Then, we turned to the construction of C_{17} – C_{23} fragment of didemnaketals (Scheme 3). Conjugative ketone **16** was prepared from (*R*)-pulegone **8** in 56% yield through five steps.² Reduction of ketone **16** with NaBH_4 followed by protection of the formed hydroxyl group with TBDPSCl afforded alkene **18**. Then, the diol **19** was produced through the stereoselective osmylation⁷ of the double bond in compound **18**. Subsequently, selective protection of the secondary hydroxyl group in the diol **19** afforded the intermediate **20**. Fortunately, elimination of the tertiary hydroxyl group in **20**, gave compound **21** with the double bond in six-membered ring (no other isomer was found). Ozonolysis of **21** produced the open-chain keto-aldehyde **22**. Selective reduction of the aldehyde group in **22** followed by thioacetalization and iodination with iodine afforded the iodide **25**, whose absolute stereochemistry was conformed by X-ray (Fig. 1). This iodide **25** was converted to the sulfone **26** and deprotection of **26** produced the diol **27**. Protection of the diol **27** with DMP afforded the sulfone **7** as a C_{17} – C_{23} fragment of didemnaketals.

The coupling of **6** and **7** was carried out as shown in Scheme 4. Deprotonation of the sulfone **6** with n -BuLi and subsequent reaction with aldehyde **7** afforded the α -hydroxy sulfone **28**. Subsequently, oxidation of the hydroxyl group of **28** with Collins reagent⁸ and then removal of the sulfone with 6% sodium amalgam gave compound **5** a single isomer as the open-chain polyhydroxyl ketone intermediate **5**. Deprotection of the hydroxyl groups with hydrofluoric acid triggered deprotection and subsequent spirocyclization to afford the final spiroketal **4** as the single product.⁹ Thus, we have succeeded in the stereocontrolled synthesis of the key mother spiroketal C_9 – C_{23} portion of the HIV-1 protease inhibitive didemnaketals, in which the eight stereocenters (10*S*, 11*S*, 12*S*, 14*S*, 16*S*, 18*R*, 20*S*, and 21*S*) were constructed successfully. Further, study toward total synthesis of the didemnaketals is ongoing in our group.

Acknowledgments


We are grateful for the financial support of the Natural Science Foundation of China (NSFC Nos. 29925205, 30271488, 20021001, 203900501).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2005.07.167.

References and notes

- (a) Potts, B. C. M.; Faulkner, D. J.; Chan, J. A.; Simolike, G. C.; Offen, P. M.; Hemling, E.; Francis, T. A. *J. Am. Chem. Soc.* **1991**, *113*, 6321; (b) Pika, J.; Faulkner, D. *Nat. Prod. Lett.* **1995**, *7*, 291.
- (a) Jia, Y. X.; Wu, B.; Li, X.; Ren, S. K.; Tu, Y. Q.; Chan, A. S. C.; Kitching, W. *Org. Lett.* **2001**, *3*, 847; (b) Jia, Y. X.; Li, X.; Wu, B.; Zhao, X. Z.; Tu, Y. Q. *Tetrahedron* **2002**, *58*, 1697.
- Salomon, C. E.; Williams, D. H.; Lobkovsky, E.; Clardy, J. C.; Faulkner, D. J. *Org. Lett.* **2002**, *4*, 1699.
- Zhao, X. Z.; Tu, Y. Q.; Peng, L.; Li, X. Q.; Jia, Y. X. *Tetrahedron Lett.* **2004**, *45*, 3713.
- The configuration of **11** was determined from its acetonide derivative **29**. The stereochemistry of **29** was conformed through ^1H NMR NOE experiment as shown below. For example, irradiation of $\text{C}_{11}\text{--H}$ (δ : 3.73 ppm) lead to 5% enhancement of $\text{C}_9\text{--H}$ (δ : 1.33 ppm), and 4% enhancement of $\text{C}_{13}\text{--H}$ (δ : 1.57 ppm), and irradiation of $\text{C}_{12}\text{--H}$ (δ : 3.47 ppm) lead to 5% enhancement of $\text{C}_{17}\text{--H}$ (δ : 1.25 ppm), and 3% enhancement of $\text{C}_{18}\text{--H}$ (δ : 1.00 ppm).



- Still, W. C.; Barrish, J. C. *J. Am. Chem. Soc.* **1983**, *105*, 2487.

7. Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483.
8. (a) Collins, J. C.; Hess, W. W.; Frank, F. J. *Tetrahedron Lett.* **1968**, *9*, 3363; (b) Ratcliffe, R.; Rodehorst, R. *J. Org. Chem.* **1970**, *35*, 4000.
9. The analytical data of the compound **4**: $[\alpha]_{\text{D}}^{17} +32.0$ (*c* 0.2, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ : 4.55 (dd, 1H, *J* = 1.6, 9.6 Hz), 4.07 (dd, 1H, *J* = 2.8, 12.4 Hz), 3.74–3.66 (m, 3H), 3.66 (dd, 1H, *J* = 3.2, 11.2 Hz), 2.94–2.86 (m, 2H), 2.83 (dd, 1H, *J* = 3.6, 8.4 Hz), 2.80–2.74 (m, 2H), 2.10–2.04 (m, 2H), 2.01–1.92 (m, 4H), 1.70 (s, 3H), 1.52–1.47 (m, 3H), 1.31–1.28 (m, 1H), 1.24 (d, 3H, *J* = 6.8 Hz), 1.15–1.09 (m, 1H), 1.04–0.94 (m, 1H), 0.88 (d, 3H, *J* = 6.4 Hz), 0.84 (d, 3H, *J* = 7.2 Hz); ¹³C NMR (100 MHz) δ : 99.2, 78.6, 76.4, 71.2, 68.3, 63.3, 53.8, 44.3, 40.2, 36.1, 35.1, 30.7, 26.2, 26.1, 25.0, 24.8, 24.5, 24.0, 22.2, 20.7, 13.6; FAB-MS (M+Li)⁺: *m/z* 441; (M+Na)⁺: *m/z* 457; HR-ESIMS: *m/z* calcd for C₂₁H₃₈S₂O₅Na (M+Na) 457.2053; found 457.2065.